Rajiv Amin - 10 Mar 2023 Form 3 Insider Report for IMPEL PHARMACEUTICALS INC

Reporting relationship
VP, Controller & Interim CFO
Issuer ticker
N/A
Reported as of
10 Mar 2023
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
10 Mar 2023, 15:33:40 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Adrian Adams as attorney-in-fact

Key filing fact

Rajiv Amin filed Form 3 for IMPEL PHARMACEUTICALS INC on 10 Mar 2023.

Key facts

  • This page summarizes Rajiv Amin's Form 3 filing for IMPEL PHARMACEUTICALS INC.
  • 0 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 10 Mar 2023, 15:33.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMPL holding

No securities beneficially held

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
0
Date
10 Mar 2023
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMPL holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Mar 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
15,500
Exercise price
$10.02
Footnotes
F1
IMPL holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Mar 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,000
Exercise price
$12.16
Footnotes
F2
IMPL holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Mar 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,500
Exercise price
$9.85
Footnotes
F3
IMPL holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Mar 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,000
Exercise price
$2.29
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The option vests as to 25% of the total shares on July 13, 2022, then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on July 13, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.

Footnote F2

The option vests as to 2.0833% of the total shares on August 22, 2021 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on July 22, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.

Footnote F3

The option vests as to 2.0833% of the total shares on February 26, 2022 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on January 26, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.

Footnote F4

The option vests as to 2.0833% of the total shares on March 14, 2023 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on February 14, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.

SEC remarks

Exhibit 24.1 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .